Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Rectal Cancer

153 clinical trials

138 products

42 drugs

Product
MDX2001
Product
UCMYM802
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
CEA-targeted CAR-T cells
Clinical trial
Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Capecitabine
Clinical trial
A Phase II, Randomized, Open Label, Parallel-group Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-11-21
Product
Atezolizumab
Product
Fluorouracil
Product
Tiragolumab
Product
Labetuzumab Govitecan
Clinical trial
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Status: Terminated, Estimated PCD: 2017-01-03
Clinical trial
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Product
BI 754091
Product
VSV-GP128
Product
ATP128
Clinical trial
Organ Preservation for Patients With Locally Advanced Rectal Adenocarcinoma: Evaluating the Efficacy of Short Course Radiation Therapy Followed by FOLFOX or CapeOX
Status: Recruiting, Estimated PCD: 2025-10-15
Drug
5-FU
Clinical trial
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Recruiting, Estimated PCD: 2028-06-01
Product
A2B694
Clinical trial
A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
CTX-009
Product
Panitumumab
Product
Bevacizumab
Clinical trial
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2012-05-30
Product
mFOLFOX6
Product
Fruquintinib
Product
GB104
Clinical trial
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-13
Clinical trial
Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal
Status: Completed, Estimated PCD: 2019-01-03
Clinical trial
Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Axalimogene filolisbac
Clinical trial
Open-label, Single-center, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety and Tolerability of GB104, and Explore Gut Microbial Composition in Patients Who Completed Curative Colectomy and Planned Therapy of Colorectal Cancer
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Status: Completed, Estimated PCD: 2022-01-12
Product
A166
Clinical trial
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Terminated, Estimated PCD: 2015-06-22
Product
E7820
Product
FOLFIRI
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Systemic Treatment
Drug
FOLFOXIRI
Drug
mFOLFOX6
Clinical trial
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver
Status: Completed
Product
floxuridine
Product
Leucovorin
Product
melphalan
Clinical trial
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Status: Withdrawn, Estimated PCD: 2024-02-09
Drug
Regorafenib
Product
XmAb20717
Clinical trial
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Tislelizumab
Clinical trial
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Product
LY2880070
Drug
Gemcitabine
Clinical trial
Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)
Status: Active (not recruiting), Estimated PCD: 2022-03-06
Product
Cu 64 anti-CEA monoclonal antibody M5A
Clinical trial
Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer
Status: Withdrawn, Estimated PCD: 2024-06-30
Product
Signatera
Clinical trial
A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Ipilimumab
Product
Nivolumab
Clinical trial
A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.
Status: Recruiting, Estimated PCD: 2026-02-01
Product
SGM-101
Clinical trial
Non Inferiority Multicenter Phase III Randomized Trial Comparing Preoperative Chemotherapy Only to Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer (Intergroup FRENCH-GRECCAR- PRODIGE)
Status: Recruiting, Estimated PCD: 2026-12-05
Drug
Cisplatin
Product
Radiochemotherapy
Clinical trial
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2023-07-14
Product
Trametinib
Clinical trial
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Etrumadenant
Clinical trial
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial
Status: , Estimated PCD: 2030-12-31
Clinical trial
Organ Preservation With Active Surveillance After Chemoradiation in Rectal Cancer (OPTION)
Status: Recruiting, Estimated PCD: 2026-10-31
Product
Trifluridine and Tipiracil
Clinical trial
Multicenter Retrospective Trial for Analysis of Oncological Results of Patients With Primary Rectal Cancer Operated on Between 2013-2019
Status: Active (not recruiting), Estimated PCD: 2022-12-30
Drug
Metformin
Clinical trial
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Status: Completed, Estimated PCD: 2024-04-08
Product
Folfox Protocol
Product
Capox
Product
FOLFOX
Product
Zimberelimab
Clinical trial
Chemoradiation OR Brachytherapy for RECTal Cancer
Status: Completed, Estimated PCD: 2021-09-30
Drug
FOLFOX6
Clinical trial
Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)
Status: Recruiting, Estimated PCD: 2025-01-31
Product
SX-682
Clinical trial
Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen
Status:
Drug
interleukin-2
Product
MAGE-12
Product
Montanide ISA-51
Clinical trial
No Operation After Short Course Equivalent Dose (Ht) Radiation Therapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer: The Prospective, Single Arm NOAHS-ARC Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Drug
5-Fluoracil
Clinical trial
Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer (mRCAT): An Open-label, Single-arm, Prospective Multicenter Clinical Trial
Status: Recruiting, Estimated PCD: 2025-05-01
Drug
PD-1 antibody
Clinical trial
Preoperative ChemoRadiation And FOLFOXIRI To Escalate Complete Response for Rectal Cancer (CRAFTER)
Status: Recruiting, Estimated PCD: 2024-01-30
Product
combination of drugs
Clinical trial
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer: A Phase II Study
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (Trifluridine/Tipiracil) With Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer (FIERCE)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Vactosertib
Drug
fludarabine
Clinical trial
A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal Cancers
Status: Completed, Estimated PCD: 2021-09-29
Drug
trametinib
Drug
fluorouracil
Clinical trial
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Status: Active (not recruiting), Estimated PCD: 2022-11-01
Product
Cetuximab
Product
Irinotecan
Clinical trial
Phase I Pilot Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in the Adjuvant Setting in Patients With Colorectal, Pancreatic, or Lung Cancer
Status:
Product
Detox-B
Clinical trial
Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical Trial
Status: Completed, Estimated PCD: 2024-03-15
Clinical trial
Single Arm and Phase II Clinical Trial of a Sandwich Regimen as XELOX Regimen and Capecitabine Alternate Administration Combined With Preoperative Intensity Modulated Radiation Therapy for pMMR Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2027-05-01
Drug
XELOX
Clinical trial
Sequential Combined TAS-102 and Oxaliplatin Alternating With TAS-102 and Irinotecan (Sequential TASOXIRI) With Bevacizumab for Late-Line Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2026-05-01
Product
TAS-102
Clinical trial
A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers
Status: Recruiting, Estimated PCD: 2024-12-31
Product
1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Clinical trial
A Phase II Study of Total Neoadjuvant Therapy in Rectal Cancer
Status: Recruiting, Estimated PCD: 2026-11-16
Clinical trial
A Single-arm, Phase II Clinical Trial to Treat Locally Advanced, pMMR Rectal Cancer With Single-agent Trifluridine/Tipiracil Chemotherapy Plus Neoadjuvant Intensity-modulated Radiotherapy
Status: Not yet recruiting, Estimated PCD: 2028-12-31
Product
Trifluridine/Tipiracil
Clinical trial
Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
Status: Active (not recruiting), Estimated PCD: 2022-07-26
Product
PDS0101
Product
M7824
Product
NHS-IL12
Product
Ras Peptide Cancer Vaccine
Clinical trial
A Single-arm, Multicenter, Phase II Clinical Study of Chemoradiotherapy Followed by Tislelizumab Combined With Chemotherapy for Organ Preservation in Resectable Low Rectal Cancer：the RELIEVE-01 Study
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Neoadjuvant Treatment of Locally Advanced MSS Rectal Cancer With Tislelizumab Combined With CAPOX Regimen: a Prospective, Single-arm, Single-center, Exploratory Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-10-14
Product
Oxaliplatin
Product
5FU
Product
Folinic Acid
Clinical trial
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Single-Arm, Phase 2 Trial
Status: Recruiting, Estimated PCD: 2024-01-01
Product
Sintilimab
Clinical trial
Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients. A Phase I Trial of the German Rectal Cancer Study Group
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Kineret
Clinical trial
Efficacy and Safety of Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy for RAS Wild-type Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-08-31
Product
cetuximab+mFOLFOX6
Clinical trial
A Randomized Phase 2 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With and Without BMX-001 as Part of Total Neoadjuvant Therapy in Patients With Newly Diagnosed Locally Advanced Rectal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2027-05-01
Product
BMX-001
Clinical trial
An Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC
Status: Not yet recruiting, Estimated PCD: 2027-03-21
Product
Fuquinitinib + Tegafur Gimeracil Oteracil
Clinical trial
Short Course Radiotherapy With Total Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Status: , Estimated PCD: 2020-09-30
Product
Immunotherapy
Clinical trial
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group
Status: Completed, Estimated PCD: 2018-09-01
Product
Induction Chemotherapy
Product
Chemotherapy arm B
Clinical trial
Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2027-07-15
Product
Epacadostat
Product
CAPOX chemotherapy
Clinical trial
Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
Status: Recruiting, Estimated PCD: 2027-10-01
Product
Camrelizumab
Clinical trial
A Multicenter, Randomized, Open-label, Controlled Phase III Clinical Trial of Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in the Treatment for Locally Advanced Rectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-03-01
Product
Short course radiotherapy sequential camrelizumab and chemotherapy
Clinical trial
Immunotherapy in Patients With Early dMMR Rectal Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Pertuzumab
Clinical trial
Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery of Locally Advanced Rectal Cancer Using Cetuximab-IRDye800CW: a Single-center Feasibility and Safety Study
Status: Completed, Estimated PCD: 2022-01-28
Product
Cetuximab-IRDye800
Clinical trial
A Single-arm, Single-center, Prospective Clinical Study of Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody for Neoadjuvant Therapy of PMMR/MSS Type Middle and Low Locally Advanced Rectal Cancer
Status: Not yet recruiting, Estimated PCD: 2028-12-31
Product
Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
Clinical trial
Phase II of Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in Primary High-risk Rectal Cancer
Status: Active (not recruiting), Estimated PCD: 2020-05-30
Product
Capecitabine + Oxaliplatin
Drug
Trastuzumab
Clinical trial
Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo With/Without Bevacizumab (mAB to Vascular Endothelial Growth Factor-A) in Patients With Resected Hepatic Metastases From Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
Bevacizumab HAI plus systemic chemotherapy
Product
HAI plus systemic chemotherapy
Clinical trial
Pilot Study: Imaging Tumor Extent and Response Before and After Neoadjuvant Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)
Status: Recruiting, Estimated PCD: 2025-11-12
Product
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A
Clinical trial
Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]
Status: , Estimated PCD: 2023-12-31
Drug
AN0025
Clinical trial
Intérêt de la rééducation érectile précoce Par Sildénafil après radiothérapie et Proctectomie Pour Cancer du Rectum : Essai contrôlé randomisé
Status: Not yet recruiting, Estimated PCD: 2028-05-01
Product
Sildenafil
Clinical trial
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
Status: Recruiting, Estimated PCD: 2028-01-01
Drug
mFOLFIRINOX
Drug
UTD1
Product
Tolinapant
Product
FOLFOX4
Drug
CAPOX
Clinical trial
A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-09
Product
Cabozantinib
Drug
T-VEC
Clinical trial
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-06-22
Drug
Atezolizumab
Clinical trial
Exploratory Study on the Efficacy and Safety of Long-course Neoadjuvant Chemoradiation With Liposomal Irinotecan and Capecitabine Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Product
Liposomal irinotecan
Product
Dasatinib
Clinical trial
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Status: Terminated, Estimated PCD: 2021-07-31
Product
Savolitinib
Clinical trial
Phase 2 Study of Total Neoadjuvant mFOLFOX and Short-Course Radiotherapy in Resectable Rectal Cancer
Status: Recruiting, Estimated PCD: 2028-01-31
Drug
Docetaxel
Clinical trial
A Phase III, Multi-institutional Randomised Trial Comparing Neoadjuvant Chemoradiotherapy (NARCT) and Total Neoadjuvant Therapy (TNT) in Patients With T3 (a/b/c) Rectal Cancer
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
Neoadjuvant Chemoradiotherapy
Product
Total Neoadjuvant Therapy
Clinical trial
Combined Chemotherapy and Tislelizumab With Preoperative Split-course Hypofraction Radiotherapy for Locally Advanced Rectal Cancer:Study Protocol of a Prospective, Single-arm Phase II Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-12-01
Drug
cyclophosphamide
Clinical trial
GI-116: Phase II Study of Organ Preservation in Early Rectal Cancer Patients
Status: , Estimated PCD: 2025-03-01
Product
anti-KRAS G12D mTCR PBL
Clinical trial
Visualization of a VEGF-targeted Optical Fluorescent Imaging Tracer in Rectal Cancer During Flexible NIR Fluorescence Endoscopy
Status: Completed, Estimated PCD: 2016-12-01
Product
Bevacizumab-IRDye800CW
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-06-29
Product
Anti-KRAS G12V mTCR PBL
Clinical trial
A Multicenter, Randomized Controlled Trial of Preoperative Sequential Short-course Radiation Therapy and Oxaliplatin-based Consolidation Chemotherapy for Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Novel Objective Comparison of Short-term Surgical Outcomes From Total Mesorectal Excision Between Total Neoadjuvant Therapy - Rapido Protocol, Standard Long Course Radiotherapy and Upfront Surgery
Status: Active (not recruiting), Estimated PCD: 2022-05-31
Product
RAPIDO TNT
Product
LCRT
Clinical trial
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Product
Tretinoin
Clinical trial
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer
Status: Not yet recruiting, Estimated PCD: 2030-01-30
Product
Fluoruracil
Clinical trial
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Status: Active (not recruiting), Estimated PCD: 2020-12-01
Clinical trial
Multicenter Prospective Randomized Clinical Trial of Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Xintilimab
Clinical trial
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-12-30
Drug
Tucatinib
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Adavosertib
Clinical trial
68Ga-FAPI-04 PET Imaging in Early Response Evaluation of Rectal Cancer Patients Treated With Immunotherapy: A Single-center Clinical Study
Status: Recruiting, Estimated PCD: 2023-12-31
Product
68Ga-FAPI-04
Drug
18F-FDG
Product
Afatinib
Product
Binimetinib
Clinical trial
A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer
Status: Terminated, Estimated PCD: 2022-11-11
Clinical trial
Clinical Application of Efficacy Prediction Model Based on Epigenetics Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Terelizumab
Drug
CapeOx
Clinical trial
A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients
Status: Completed, Estimated PCD: 2019-02-19
Product
6,8-bis(benzylthio)octanoic acid
Clinical trial
Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-01-01
Product
CB-839
Clinical trial
A Prospective, Multicenter, Randomized Controlled Trial of Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-12
Product
Concurrent Chemoradiotherapy
Product
mFOLFOX
Clinical trial
A Multicenter Single-arm Phase 2 Study to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy of Short Course Radiation Therapy Followed by Neoadjuvant Oxaliplatin/Fluorouracil-based Chemotherapy (CAPOX) for cT2 Rectal Cancer.
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Status: Completed, Estimated PCD: 2020-04-21
Product
Veliparib
Clinical trial
The Role of Surgery of the Primary Tumour With Few or Absent Symptoms in Patients With Synchronous Unresectable Metastases of Colorectal Cancer, a Randomized Phase III Study. A Study of the Dutch Colorectal Cancer Group (DCCG)
Status: Completed, Estimated PCD: 2022-06-01
Product
Systemic treatment
Clinical trial
One Arm Exploratory Trial of Efficacy and Safety of TNT Plus Mode With Neoadjuvant Radiotherapy in the Treatment of Locally Advanced Medium-low Rectal Cancer
Status: Not yet recruiting, Estimated PCD: 2024-11-10
Product
CapeOX + Cetuximab
Product
CapeOX + Bevacizumab
Clinical trial
SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial
Status: Completed, Estimated PCD: 2023-12-14
Drug
TAS 102
Clinical trial
Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma: An Prospective, Single Center, Single Arm Study
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Envafolimab
Clinical trial
An Adaptative Randomized Phase II Study on the Timing of FOLFOX for Patients With Operable Stage III Rectal Cancer
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer; A Prospective Randomised Phase 2 Study Stratified by MGMT (O6-methylguanine DNA Methyltransferase) Status
Status: Completed, Estimated PCD: 2021-02-02
Product
Capecitabine plus temozolomide
Clinical trial
Efficacy and Safety of Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy for RAS Mutant-type Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Bevacizumab+mFOLFOX6
Clinical trial
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma: a Prospective, Multicenter, Randomized Controlled Study (PRECAM-R)
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Clinical Trial of Sentinel Lymph Node Biopsy in Rectal Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Indocyanine green
Clinical trial
Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy
Status: Terminated, Estimated PCD: 2013-10-01
Product
AZD6244
Product
Cediranib
Clinical trial
Randomized Control Trial Comparing Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Status: Completed, Estimated PCD: 2023-03-23
Product
Rifaximin
Drug
Varlilumab
Clinical trial
Randomized Trial to Compare Propofol to Fentanyl and Midazolam for Colonoscopy.
Status: Completed, Estimated PCD: 2015-03-01
Drug
Ketamine
Product
Propofol
Product
Midazolam
Clinical trial
A Phase II Study of Neoadjuvant FOLFOXIRI Followed by Concurrent Capecitabine and Radiotherapy for High Risk Rectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
neoadjuvant FOLFOXIRI
Clinical trial
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Drug
mFOLFOXIRI
Clinical trial
Phase II Trial PD-L1/PD-1 Blockade Avelumab (MSB0010718C) With Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer
Status: Completed, Estimated PCD: 2023-02-28
Product
Avelumab
Clinical trial
Prospective Single-arm Phase II Clinical Study of Fruquintinib Combined With Toripalimab and SRT in Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for MRF-negative Locally Advanced, pMMR Rectal Cancer: a Randomised, Phase 2 Trial
Status: Recruiting, Estimated PCD: 2025-03-01
Drug
AK104
Clinical trial
Non-OpeRative MANagement of Rectal Cancer Patients Who Had Clinical Complete Response After Pre-operative Chemo-raDiotherapY
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Phase II, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of Serial Endoscopic Surveillance (SES) and Direct Topical Antibiotics (DTA) to Define the Role of Microbes in Anastomotic Healing
Status: Withdrawn, Estimated PCD: 2017-03-03
Product
Cipro, Metronidazole, Neomycin Combo
Clinical trial
KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
A Phase II Study to Explore the Neoadjuvant Treatment of Serplulimab Combined With CAPEOX + Celecoxib in the Treatment of Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-02-20
Product
Serplilumab
Drug
Celecoxib
Clinical trial
The Efficacy of Intraoperative ICG Angiography in Assuring Optimal Blood Supply to the Anastomosis in Rectal Cancer Patients Undergoing Laparoscopic Anterior Resection
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Verdye Green
Clinical trial
Alterations of Gut Microbiome, Function, and Its Intervention After Total Mesorectal Excision With Defunctioning Ileostomy for Mid-low Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-07-17
Product
MIYAIRI 588
Clinical trial
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial
Status: Recruiting, Estimated PCD: 2023-12-01
Product
TMZ
Clinical trial
Phase II Trial of Organ Preservation Program Using Short-Course Radiation and FOLFOXIRI for Rectal Cancer (SHORT-FOX)
Status: Active (not recruiting), Estimated PCD: 2024-01-17
Clinical trial
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Status: , Estimated PCD: 2026-12-31
Drug
Lurbinectedin
Clinical trial
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trial
Status: Completed, Estimated PCD: 2021-01-11
Product
Aflibercept
Clinical trial
Evaluation of 64Cu-ATSM PET/CT in Predicting Neo Adjuvant Treatment Response in Locally Advanced Rectum Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Drug
64Cu-ATSM
Clinical trial
Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2012-09-01
Drug
aflibercept
Clinical trial
A Phase I/II Study to Evaluate the Safety and Feasibility of Multimodal Imaging Using a Dual-labeled Anti-CEA Antibody in Patients With Rectal or Pancreatic Cancer
Status: Not yet recruiting, Estimated PCD: 2025-05-02
Product
In-DOTA-ANTI-CEA antibody
Clinical trial
Induction Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan) Followed by Short Course Radiotherapy in Locally Advanced Rectal Cancer
Status: Active (not recruiting), Estimated PCD: 2022-11-30
Product
FOLFIRINOX
Clinical trial
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Sevoflurane
Product
Lidocaine
Clinical trial
Long-course Concurrent Chemoradiotherapy Combined With Camrelizumab in the Neoadjuvant Treatment of Locally Advanced/Low Anus-preserving Rectal Cancer: a Phase II Single-arm Study.
Status: Not yet recruiting, Estimated PCD: 2026-08-16
Clinical trial
Improving Detection and Treatment of Locally Advanced Rectal Cancer by Dual Wavelength Quantitative Fluorescence Molecular Endoscopy Using Nivolumab-800CW and Durvalumab-680LT
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Drug
nivolumab
Clinical trial
Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA)
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Dietary fiber capsules
Clinical trial
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait. A Multi-center Prospective Randomized Controlled Trial. (CCHOWW)
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Prospective, Open-Label, Single-Arm and Multicentre Phase II Study to Explore the Efficacy and Safety of Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Middle and Lower Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Total Neoadjuvant Therapy With Split-course Hypofraction Radiotherapy Combined With CAPOX and Envafolimab Followed by Local Excision for Locally Advanced Very Low Rectal Cancer: an Open-label, Single-arm, Multi-center, Phase II Trial
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum
Status: Terminated, Estimated PCD: 2022-03-22
Product
Talimogene Laherparepvec
Clinical trial
Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy
Status: Active (not recruiting), Estimated PCD: 2022-06-09
Product
Neoadjuvant chemotherapy Folfirinox
Clinical trial
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Status: Terminated, Estimated PCD: 2015-04-01
Drug
oxaliplatin
Drug
bevacizumab
Clinical trial
Randomized Trial of Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy to Patients With Early Low and Mid Rectal Cancer: The Watchful Waiting 3 Trial (WW3)
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial
Status: Recruiting, Estimated PCD: 2023-04-01
Clinical trial
A Randomized Study of Neoadjuvant Chemoradiotherapy With or Without Intensification With the FOLFOXIRI Chemo-regimen for High-risk Locally Advanced Rectal Cancer
Status: Recruiting, Estimated PCD: 2024-03-31
Drug
rituximab
Product
Experimental arm
Clinical trial
Risk-Adapted Therapy for HIV-Associated Anal Cancer
Status: Recruiting, Estimated PCD: 2029-09-15
Clinical trial
Proactive Management of Endoperitoneal Spread in Colonic Cancer
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
Standard adjuvant systemic chemotherapy
Clinical trial
A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
5-Fluorouracil
Clinical trial
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Open-label, Multicenter, Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
CapeOX
Product
Fruquintinib + Tislelizumab + mCapeOX
Clinical trial
Prophylactic Oral Mesalamine for the Prevention of Immune-Related Colitis in Patients Treated With Ipilimumab/Nivolumab
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
Mesalamine
Clinical trial
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)
Status: Not yet recruiting, Estimated PCD: 2026-02-28
Product
NG-350A